Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Merck, the third-largest pharma R&D spender in 2021, has enlisted outside help in funding its mid-stage schizophrenia program as the Big Pharma looks to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Roy­al­ty Phar­ma bets Mer­ck­'s schiz­o­phre­nia drug can go where Pfiz­er, Take­da and Lund­beck­'s couldn’t

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Royalty Pharma bets Merck's schizophrenia drug can go where Pfizer, Takeda and Lundbeck's couldn’t

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?